{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transitional+Cell+Bladder+Cancer",
    "query": {
      "condition": "Transitional Cell Bladder Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 351,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transitional+Cell+Bladder+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:33:54.966Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03945162",
      "title": "Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG"
      ],
      "interventions": [
        {
          "name": "Ruvidar® (TLD-1433) bladder infusion and PDT",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Theralase® Technologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2019-08-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 10,
      "location_summary": "Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Greenwood",
          "state": "Indiana"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Gahanna",
          "state": "Ohio"
        },
        {
          "city": "Bala-Cynwyd",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945162"
    },
    {
      "nct_id": "NCT06138561",
      "title": "Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Metastatic Bladder Cancer",
        "Unresectable Bladder Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Geriatric-8 Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2024-03-05",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06138561"
    },
    {
      "nct_id": "NCT03039413",
      "title": "Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Bladder Urothelial Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Copper Cu 64 TP3805",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-09-28",
      "completion_date": "2024-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03039413"
    },
    {
      "nct_id": "NCT04440943",
      "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "MSI-H Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CDX-527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-08-04",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04440943"
    },
    {
      "nct_id": "NCT02699853",
      "title": "Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage 0is Bladder Urothelial Carcinoma",
        "Stage I Bladder Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma",
        "Stage III Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radical Cystectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2016-04-12",
      "completion_date": "2018-11-16",
      "has_results": false,
      "last_update_posted_date": "2019-05-03",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02699853"
    },
    {
      "nct_id": "NCT02688348",
      "title": "Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-04-22",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688348"
    },
    {
      "nct_id": "NCT04200963",
      "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder",
        "Bladder Cancer",
        "Bladder Disease",
        "Solid Tumor",
        "Solid Carcinoma",
        "Solid Tumor, Adult",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Metastatic Bladder Cancer",
        "Metastatic Urothelial Carcinoma",
        "Locally Advanced Solid Tumor",
        "Neoplasms",
        "Neoplasm Metastasis",
        "Neoplasm Malignant",
        "Neoplasm, Bladder",
        "Urothelial Neoplasm",
        "Neoplasm, Urinary Bladder",
        "Bladder Neoplasm",
        "Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "IK-175",
          "type": "DRUG"
        },
        {
          "name": "IK-175 and nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-12-18",
      "completion_date": "2023-07-18",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200963"
    },
    {
      "nct_id": "NCT03171493",
      "title": "Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "MV-NIS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vyriad, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-07-20",
      "completion_date": "2023-05-12",
      "has_results": false,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03171493"
    },
    {
      "nct_id": "NCT00022633",
      "title": "S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 65,
      "start_date": "2001-07",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-11",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 92,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valdosta",
          "state": "Georgia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022633"
    },
    {
      "nct_id": "NCT04637594",
      "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2022-05-27",
      "completion_date": "2030-09",
      "has_results": true,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-05-22T05:33:54.966Z",
      "location_count": 377,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04637594"
    }
  ]
}